Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H30O2 |
Molecular Weight | 302.451 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)C=C[C@]34C
InChI
InChIKey=JRNSSSJKIGAFCT-YDSAWKJFSA-N
InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,13,15-17,22H,4-5,7-8,10-12H2,1-3H3/t13-,15+,16-,17-,18-,19-,20-/m0/s1
Methyl-1-testosterone(M1T)(17alpha-hydroxy-17-methyl-
5-androst-1-en-3-one) is a new designer steroid that is most likely produced to circumvent
the legal restrictions. It is advertised to be highly
anabolic and moderately androgenic and not convertible
to estrogens. However, in scientific literature, it was reported
to show anabolic properties of 25% and androgenic
properties of 50% compared with testosterone propionate
after im injection in castrated rats. In February
2006, Health Canada (Federal Department) warned consumers
not to use M1T-containing products because of
potentially serious health risks such as liver disorders and
hardening of the arteries. Since 2006, M1T is explicitly listed on the
World Anti-Doping Agency list of prohibited substances,
and therefore, its use by athletes is prohibited.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21990312 |
3.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
[Component analysis of a new anabolic androgenic steroid and its monitoring research in human urine]. | 2010 Jan |
|
Endocrine characterization of the designer steroid methyl-1-testosterone: investigations on tissue-specific anabolic-androgenic potency, side effects, and metabolism. | 2011 Dec |
|
Acute Kidney Injury Due to Interaction of Methyl-1-testosterone with Ciclosporin Metabolism in a Patient with Severe Atopic Dermatitis. | 2013 Dec |
Sample Use Guides
For amplifying performance and physique gains, recommended dosages range from 5mg to 20mg. Dosages above 20mg is not recommended.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21990312
In the yeast androgen screen (YAS), M1T induced AR-dependent gene activity
in a dose-dependent manner. The EC50 was consistent
with the EC50 of the reference DHT (3 x 10-9 M).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-Methyl-1-testosterone
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID20879831
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
PRIMARY | |||
|
DB01572
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
PRIMARY | |||
|
65-04-3
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
PRIMARY | |||
|
7092657
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
PRIMARY | |||
|
18167-94-7
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
METHYL-1-TESTOSTERONE
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
PRIMARY | |||
|
21O907N0NH
Created by
admin on Sat Dec 16 08:03:19 GMT 2023 , Edited by admin on Sat Dec 16 08:03:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY